Nothing Special   »   [go: up one dir, main page]

MX2024001313A - Tratamiento del cancer con combinaciones de espironolactona y acilfulvenos. - Google Patents

Tratamiento del cancer con combinaciones de espironolactona y acilfulvenos.

Info

Publication number
MX2024001313A
MX2024001313A MX2024001313A MX2024001313A MX2024001313A MX 2024001313 A MX2024001313 A MX 2024001313A MX 2024001313 A MX2024001313 A MX 2024001313A MX 2024001313 A MX2024001313 A MX 2024001313A MX 2024001313 A MX2024001313 A MX 2024001313A
Authority
MX
Mexico
Prior art keywords
spironolactone
acylfulvenes
combinations
treating cancers
derivative
Prior art date
Application number
MX2024001313A
Other languages
English (en)
Inventor
Aditya Kulkarni
Kishor Bhatia
Jianli Zhou
Original Assignee
Lantern Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantern Pharma Inc filed Critical Lantern Pharma Inc
Publication of MX2024001313A publication Critical patent/MX2024001313A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un método para tratar el cáncer incluye una combinación de una cantidad terapéuticamente efectiva de una iludina o un análogo de iludina de esta, derivado, o una sal farmacéuticamente aceptable de esta; y una cantidad terapéuticamente efectiva de una espironolactona o un análogo, derivado, o una sal farmacéuticamente aceptable de esta. En la presente descripción se incluye las composiciones y los kits de las mismas.
MX2024001313A 2021-07-29 2022-07-29 Tratamiento del cancer con combinaciones de espironolactona y acilfulvenos. MX2024001313A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163227257P 2021-07-29 2021-07-29
PCT/US2022/074297 WO2023010107A1 (en) 2021-07-29 2022-07-29 Treating cancers with combinations of spironolactone and acylfulvenes

Publications (1)

Publication Number Publication Date
MX2024001313A true MX2024001313A (es) 2024-04-30

Family

ID=85087309

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024001313A MX2024001313A (es) 2021-07-29 2022-07-29 Tratamiento del cancer con combinaciones de espironolactona y acilfulvenos.

Country Status (8)

Country Link
EP (1) EP4376821A1 (es)
JP (1) JP2024527087A (es)
KR (1) KR20240073856A (es)
CN (1) CN117881396A (es)
AU (1) AU2022317139A1 (es)
CA (1) CA3227308A1 (es)
MX (1) MX2024001313A (es)
WO (1) WO2023010107A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11844772B2 (en) * 2020-12-29 2023-12-19 Lantern Pharma Inc. Method for treating rhabdoid tumors
WO2024187196A1 (en) * 2023-03-09 2024-09-12 Lantern Pharma Inc. Method for treating renal cell carcinoma or cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
WO2017180086A1 (en) * 2016-04-11 2017-10-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
WO2017023694A1 (en) * 2015-08-03 2017-02-09 Pop Test Oncology Llc Pharmaceutical compositions and methods
US9725769B1 (en) * 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
EP3846791A4 (en) * 2018-09-04 2022-06-08 Lantern Pharma Inc. ILLUDIN ANALOGUES, THEIR USES AND PROCEDURES FOR THEIR SYNTHESIS
JP2022513349A (ja) * 2018-10-14 2022-02-07 ランタン ファーマ インコーポレイテッド イルジンおよびバイオマーカーを使用した固形腫瘍癌の治療方法

Also Published As

Publication number Publication date
CN117881396A (zh) 2024-04-12
JP2024527087A (ja) 2024-07-19
WO2023010107A1 (en) 2023-02-02
CA3227308A1 (en) 2023-02-02
EP4376821A1 (en) 2024-06-05
KR20240073856A (ko) 2024-05-27
AU2022317139A1 (en) 2024-03-14

Similar Documents

Publication Publication Date Title
WO2020050890A3 (en) Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
MX2020012204A (es) Inhibidores de kras g12c para tratar el cáncer.
MX2024001313A (es) Tratamiento del cancer con combinaciones de espironolactona y acilfulvenos.
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
EP3938354A4 (en) CANCER TREATMENT COMPOSITIONS AND METHODS
EP3983445A4 (en) CANCER TREATMENT COMPOSITIONS AND METHODS
MX2022008099A (es) Tratamiento para el cancer con inhibidores de cdk12/13.
MX2022010515A (es) Conjugacion mediada por transglutaminasa.
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
MX2024001314A (es) Tratamiento de cánceres con combinaciones del inhibidor de parp y acilfulvenos.
EP3908601A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP4025590A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
MX2020010618A (es) Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a.
EP3968785A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
MX2023008677A (es) Derivados de urolitinas y métodos para su uso.
EP4003351A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP3965896A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
EP3930705A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
EP4110822A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
EP3969121A4 (en) METHODS AND COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER
ZA202206308B (en) Ezetimibe and curcumin for use in cancer treatment
IL288953A (en) Pharmaceutical compounds, kits and methods for the treatment of cancerous tumors
WO2023235807A3 (en) Method and compositions for treating glioblastoma with triterpenes
EP4127722A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
EP3959199A4 (en) Compositions and methods for treating ras-mutant cancers